Yellow Fever Vaccine Production Ramping Up
A new state-of-the-art Yellow Fever Vaccine production facility in the USA has been licensed by the Food & Drug Administration (FDA) and the transition of production of YF-VAX continues, said Sanofi Pasteur in a statement.
This is good news since Sanofi’s Yellow Fever vaccine has been a limited-distributed vaccine in the USA during 2019.
And, the yellow fever virus can be fatal.
The Centers for Disease Control and Prevention (CDC) says about 15 percent of people who get yellow fever develop serious illness that can be fatal.
‘We are currently reassessing the YF-VAX vaccine return to supply timing and will provide an update by the end of 2019.’
"Thus, the STAMARIL vaccine Expanded Access Program (EAP) in the USA will continue until the return of YF-VAX vaccine,’ said Sanofi.
The EAP allows the importation and use of STAMARIL vaccine in place of YF-VAX vaccine to fulfill USA yellow fever immunization demand until production of YF-VAX vaccine resumes.
The STAMARIL vaccine is manufactured by Sanofi Pasteur in France. It is a live, attenuated yellow fever vaccine that is investigational/unlicensed in the USA.
However, STAMARIL is registered and currently distributed in over 70 countries.
Recent yellow fever virus news:
- Brazil Reports Yellow Fever Fatality Rate of 23%
- Yellow Fever Vaccine Alert Issued by the UK
- 8.3 Million Sudanese Receiving Yellow Fever Vaccine
Healthcare providers and patients can find locations that can administer STAMARIL vaccine by visiting this CDC web page.
Providers and patients may also visit here for information about which countries require yellow fever vaccination for entry and for which countries the CDC recommends yellow fever vaccination.
Yellow fever virus is a mosquito-borne flavivirus that causes yellow fever, an acute infectious disease.
Pre-trip vaccine counseling sessions can be scheduled at Vax-Before-Travel.
Sanofi Pasteur continuously works to improve processes to maintain a consistent supply of quality vaccines.